ZNF865 gene therapy

ZNF865 gene therapy is an experimental antineoplastic approach that utilizes CRISPR interference (CRISPRi) to downregulate the expression of the ZNF865 protein. ZNF865, also known as BLST, is a zinc finger protein that plays a critical role in regulating human cell senescence and DNA damage repair. Developed by researchers at the University of Utah, this therapy employs a lentiviral delivery system to silence ZNF865, which leads to rapid DNA damage accumulation and induces cellular senescence in cancer cells. Preclinical studies in lung adenocarcinoma (A549) cell lines have demonstrated that ZNF865 knockdown significantly inhibits clonogenic survival and invasive potential, suggesting its potential as a therapeutic target for lung and esophageal cancers.

Other names

ZNF865 knockdown therapyZNF-865 knockdown therapyZNF 865 knockdown therapyZNF865 CRISPRi therapyZNF-865 CRISPRi therapyZNF 865 CRISPRi therapyBLST gene therapy